Advertisement

Development of a novel compression-resistant carrier for recombinant human bone morphogenetic protein-2 (rhBMP-2) and preliminary clinical results

  • William F. McKay
  • Steven M. Peckham
  • Jeffrey M. Badura
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been commercially available in the United States since July 2002 (INFUSE® Bone Graft/LTCAGE ®Lumbar Tapered Fusion Device, Medtronic, Inc., Memphis, TN). It was initially approved for use in interbody spinal fusions inside a threaded titanium interbody fusion device. Since then, it has been approved for two additional clinical indications: fresh tibial fractures and certain oral maxillofacial procedures (sinus elevation and extraction sockets). The approvals were based on Level I prospective, randomized clinical trials involving the absorbable collagen sponge (ACS) carrier and rhBMP-2 at a concentration of 1.5 mg/mL.

Keywords

Interbody Fusion Tibial Fracture Fusion Device Extraction Socket Recombinant Human Bone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Burkus JK, Gornet MF, Dickman, Zdeblick TA (2002) Anterior interbody fusion using rhBMP-2 with tapered interbody cages. J Spin Disord Tech 15: 337–349Google Scholar
  2. 2.
    BESTT Study Group, Govender S, Csimma C, Genant HK, Valentin-Opran A (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg 84-A: 2123–2134Google Scholar
  3. 3.
    Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, Kregor PJ, Nordsletten L, Paiement G, Patel A (2006) Recombinant human bone morphogenetic protein-2 in open tibial fractures: A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88: 1258–1265CrossRefGoogle Scholar
  4. 4.
    Boyne PJ, Lilly LC, Marx RE, Moy PK, Nevins M, Spagnoli DB, Triplett RG (2005) De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 63: 1693–1707CrossRefGoogle Scholar
  5. 6.
    Fiorellini JP, Howell TH, Cochran D, Malmquist J, Lilly LC, Spagnoli D, Toljanic J, Jones A, Nevins M (2005) Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol 76: 605–613CrossRefGoogle Scholar
  6. 7.
    Glassman SD, Carreon LY, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar JR (2007) Posterolateral lumbar spine fusion with INFUSE® Bone Graft. Spine J 7: 44–49CrossRefGoogle Scholar
  7. 8.
    Singh K, Smucker JD, Boden SD (2006) Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: A prospective CT-scan analysis at one and two years. J Spinal Disord Tech 19: 416–423CrossRefGoogle Scholar
  8. 9.
    Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A; BMP-2 Evaluation in Surgery for Tibial Trauma-Allgraft (BESTT-ALL) Study Group (2006) Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects: A randomized controlled trial. J Bone Joint Surg 88-A: 1431–1441CrossRefGoogle Scholar
  9. 10.
    Schwartz ND, Hicks BM (2006) Segmental bone defects treated using recombinant human bone morphogenetic protein. J Orthop 3: e2Google Scholar
  10. 11.
    Akamaru T, Suh D, Boden S, Kim HS, Minamide A, Louis-Ugbo J (2003) Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spinal fusion. Spine 28: 429–434CrossRefGoogle Scholar
  11. 12.
    Schimandle JH, Boden, SD, Hutton, WC (1995) Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 20: 1326–1337CrossRefGoogle Scholar
  12. 13.
    Boden SD, Martin GJ, Horton WC, Truss TL, Sandhu HS (1998) Laparoscopic anterior spinal arthrodesis with rhbMP-2 in a titanium interbody threaded cage. J Spin Disord 11: 95–101Google Scholar
  13. 14.
    Martin GJ, Boden SD, Morone MA, Moskovitz PA (1999) Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: Important lessons learned regarding dose, carrier, and safety. J Spin Disord 12: 179–186Google Scholar
  14. 15.
    Medtronic, Inc (2000) Compare compressive resistance of absorbable collagen sponge and the calcium phosphate/collagen composite. Memphis, TN: Medtronic; Internal Technical Report — TS00-076 (PC-0013)Google Scholar
  15. 16.
    Medtronic, Inc (2007) An examination of the rhBMP-2 incorporation properties using compression resistant matrix: An in vitro study comparing commercial and clinical rhBMP-2/buffer formulations. Memphis, TN: Medtronic; Internal Technical Report — PC-0666.Google Scholar
  16. 17.
    Louis-Ugbo J, Kim HS, Boden SD, Mayr MT, Li RC, Seeherman H, D’Augusta D, Blake C, Jiao A, Peckham S (2002) Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 20: 1050–1059CrossRefGoogle Scholar
  17. 18.
    Boden SD, Martin GJ, Morone MA, Louis-Ugbo J, Moskovitz PA (1999) Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein-2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 24: 1179–1185CrossRefGoogle Scholar
  18. 19.
    Suh DY, Boden SD, Loui-Ugbo J, Mayr M, Murakami H, Kim HS, Minamide A, Hutton WC (2002) Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine 27: 353–360CrossRefGoogle Scholar
  19. 20.
    Barnes B, Boden SD, Louis-Ugbo J, Tomak PR, Park JS, Park MS, Minamide A (2005) Lower Dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine 30: 1127–1133CrossRefGoogle Scholar
  20. 21.
    Dimar JR, Glassman SD, Burkus JK, Pryor P, Hardacker J, Boden SD (2006) Evaluation of rhBMP-2/ceramic matrix as an ICBG replacement in posterolateral fusions: A multicenter Level I clinical study. International Society for the Study of the Lumbar Spine. Bergen, 58Google Scholar
  21. 22.
    Dimar JR, Glassman SD, Burkus JK, Carreon LY (2006) Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 31: 2534–2539CrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • William F. McKay
    • 1
  • Steven M. Peckham
    • 1
  • Jeffrey M. Badura
    • 1
  1. 1.Medtronic, Inc.MemphisUSA

Personalised recommendations